Novartis (NVS)
(Delayed Data from NYSE)
$115.94 USD
-0.04 (-0.03%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $116.16 +0.22 (0.19%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Novartis AG [NVS]
Reports for Purchase
Showing records 41 - 60 ( 483 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended October 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 101123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 10123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 22.
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 22.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 15.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 15.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 92123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 91123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended August 25.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 9123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 25.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 18.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended August 18.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D